D. Tuveson

Oncology · 2001–2020

A researcher in the Science corpus: 32 papers; trusts 6 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 329 citations into it; #278 of 1,698 by trust here, #33 by citations
• Molecular Biology — 323 citations into it; #5,744 of 17,773 by trust here, #612 by citations
• Cancer Research — 142 citations into it; #731 of 1,780 by trust here, #287 by citations

Whom D. Tuveson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Raghu Kalluri
2. D. Hanahan

Who trusts D. Tuveson overall

1. K. Strebhardt
2. Rakesh K. Jain
3. M. Heinrich
4. Karen H. Vousden
5. P. Muller
6. Christopher Corless
7. K. Frese
8. A. Ullrich

Papers from D. Tuveson's perspective

Ordered by how strongly the researchers D. Tuveson trusts endorse each paper. Same corpus, a different order for every researcher.

1. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. (Cancer Cell)
2. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (Genes & Development)
3. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. (Cancer Cell)
4. Hallmarks of cancer: the next generation. (Cell)
5. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. (Gastroenterology)
6. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors (Nature Genetics)
7. From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
8. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration (Nature)
9. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis (Nature)
10. Organoid cultures derived from patients with advanced prostate cancer (Cell)

Their papers

• Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis (2011) — 2,178 citations
• Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. (2005) — 2,447 citations
• Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer (2009) — 3,151 citations
• Somatic activation of the K-ras oncogene causes early onset lung cancer in mice (2001) — 1,217 citations
• Restoration of p53 function leads to tumour regression in vivo (2007) — 1,925 citations
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. (2001) — 2,034 citations
• Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. (2004) — 850 citations
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. (2004) — 1,348 citations
• Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (2003) — 1,048 citations
• Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy (2014) — 1,024 citations
• A framework for advancing our understanding of cancer-associated fibroblasts (2020) — 3,153 citations
• Fibroblast heterogeneity in the cancer wound (2014) — 857 citations
• Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α (2010) — 1,021 citations
• Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. (2019) — 1,681 citations
• Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer (2013) — 1,849 citations
• DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. (2020) — 1,033 citations
• Cancer modeling meets human organoid technology (2019) — 792 citations
• Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2018) — 839 citations
• A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (2018) — 96 citations
• IL-1-induced JAK/STAT signaling is antagonized by TGF-β to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. (2018) — 998 citations